In vivo effects of the NLRP1/NLRP3 inflammasome pathway on latent respiratory virus infection

Li,Yong‑Huai; Wei,Xiang; Ji,Shuang; Gui,Shu‑Yu; Zhang,Su‑Mei

doi:10.3892/ijmm.2018.3521

In vivo effects of the NLRP1/NLRP3 inflammasome pathway on latent respiratory virus infection

Authors:
- Yong‑Huai Li
- Xiang Wei
- Shuang Ji
- Shu‑Yu Gui
- Su‑Mei Zhang
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Laboratory of Molecular Biology and Department of Biochemistry, Anhui Medical University, Hefei, Anhui 230032, P.R. China
Published online on: February 28, 2018 https://doi.org/10.3892/ijmm.2018.3521
Pages: 3620-3628

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of nucleotide-binding domain leucine-rich repeat protein (NLRP)1/NLRP3 inflammasome pathways on latent viral infection of the respiratory tract. A total of 55 BALB/c mice were assigned to the control, bleomycin (BLM)‑treated, murine cytomegalovirus (MCMV), MCMV+BLM and MCMV+BLM+CD4+ T‑cell groups. The viral loads were detected in the salivary glands, kidney, liver and lung tissues via polymerase chain reaction (PCR). The weight, lung coefficient and hydroxyproline (HYP) were detected. HE and Masson staining were performed to score for alveolitis and degree of pulmonary fibrosis. Reverse transcription‑quantitative PCR and western blot were applied to assess the expression levels of the NLRP inflammasome components caspase‑1, interleukin (IL)‑1β and IL‑18. ELISA was used to evaluate the expression levels of caspase‑1, tumor necrosis factor (TNF)‑α, IL‑1β and IL‑18. The weight of the mice decreased, and the lung coefficient and HYP content increased in the BLM, MCMV, MCMV+BLM and MCMV+BLM+CD4+ T‑cell groups compared with those in the control group. Compared with the control group, mice in the BLM, MCMV+BLM and MCMV+BLM+CD4+ T‑cell groups had obviously increased alveolitis and degrees of pulmonary fibrosis, increased mRNA expression levels of caspase‑1, IL‑1β and IL‑18, and increased protein expression levels of caspase‑1(p20), mature IL‑1β and mature IL‑18. The values in the MCMV+BLM group were also higher than those in the BLM group and those in the MCMV+BLM+CD4+ T‑cell group. The serum levels of caspase‑1, TNF‑α, IL‑1β and IL‑18 in the serum of mice in the MCMV+BLM group were significantly higher than those in the BLM group. Compared with the MCMV+BLM group, the MCMV+BLM+CD4+ T‑cell group had decreased levels of caspase‑1, TNF‑α, IL‑1β and IL‑18 (all P<0.05). These results demonstrated that the activation of the NLRP1 and NLRP3 inflammasome pathways may contribute to pulmonary fibrosis caused by latent MCMV infection in mice.

View Figures

View References

1	Huang H, Peng X and Zhong C: Idiopathic pulmonary fibrosis: The current status of its epidemiology, diagnosis, and treatment in China. Intractable Rare Dis Res. 2:88–93. 2013.PubMed/NCBI
2	Loveman E, Copley VR, Scott DA, Colquitt JL, Clegg AJ and O'Reilly KM: Comparing new treatments for idiopathic pulmonary fibrosis-a network meta-analysis. BMC Pulm Med. 15:372015. View Article : Google Scholar
3	Lynch JP III, Huynh RH, Fishbein MC, Saggar R, Belperio JA and Weigt SS: Idiopathic Pulmonary fibrosis: Epidemiology, clinical features, prognosis, and management. Semin Respir Crit Care Med. 37:331–357. 2016. View Article : Google Scholar : PubMed/NCBI
4	King TE Jr, Pardo A and Selman M: Idiopathic pulmonary fibrosis. Lancet. 378:1949–1961. 2011. View Article : Google Scholar : PubMed/NCBI
5	Strookappe B, Elfferich M, Swigris J, Verschoof A, Veschakelen J, Knevel T and Drent M: Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: A pilot study. Sarcoidosis Vasc Diffuse Lung Dis. 32:43–52. 2015.PubMed/NCBI
6	Dempsey OJ, Kerr KM, Gomersall L, Remmen H and Currie GP: Idiopathic pulmonary fibrosis: An update. QJM. 99:643–654. 2006. View Article : Google Scholar : PubMed/NCBI
7	Spagnolo P, Rossi G and Cavazza A: Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications. Expert Rev Clin Immunol. 10:1005–1017. 2014. View Article : Google Scholar : PubMed/NCBI
8	Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, et al: Acute exacerbation of idiopathic pulmonary fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 194:265–275. 2016. View Article : Google Scholar : PubMed/NCBI
9	Fernández Pérez ER, Daniels CE, Schroeder DR, St Sauver J , Hartman TE, Bartholmai BJ, Yi ES and Ryu JH: Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: A population-based study. Chest. 137:129–137. 2010. View Article : Google Scholar
10	Finger JN, Lich JD, Dare LC, Cook MN, Brown KK, Duraiswami C, Bertin J and Gough PJ: Autolytic proteolysis within the function to find domain (FIIND) is required for NLRP1 inflammasome activity. J Biol Chem. 287:25030–25037. 2012. View Article : Google Scholar : PubMed/NCBI
11	Saresella M, La Rosa F, Piancone F, Zoppis M, Marventano I, Calabrese E, Rainone V, Nemni R, Mancuso R and Clerici M: The NLRP3 and NLRP1 inflammasomes are activated in Alzheimer's disease. Mol Neurodegener. 11:232016. View Article : Google Scholar : PubMed/NCBI
12	D'Osualdo A and Reed JC: NLRP1, a regulator of innate immunity associated with vitiligo. Pigment Cell Melanoma Res. 25:5–8. 2012. View Article : Google Scholar
13	Levandowski CB, Mailloux CM, Ferrara TM, Gowan K, Ben S, Jin Y, McFann KK, Holland PJ, Fain PR, Dinarello CA and Spritz RA: NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1β processing via the NLRP1 inflammasome. Proc Natl Acad Sci USA. 110:2952–2956. 2013. View Article : Google Scholar
14	Wang YC, Li WZ, Wu Y, Yin YY, Dong LY, Chen ZW and Wu WN: Acid-sensing ion channel 1a contributes to the effect of extracellular acidosis on NLRP1 inflammasome activation in cortical neurons. J Neuroinflammation. 12:2462015. View Article : Google Scholar : PubMed/NCBI
15	Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, Ravussin E, Stephens JM and Dixit VD: The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 17:179–188. 2011. View Article : Google Scholar : PubMed/NCBI
16	Rastrick J and Birrell M: The role of the inflammasome in fibrotic respiratory diseases. Minerva Med. 105:9–23. 2014.PubMed/NCBI
17	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the care and use of laboratory animals. Eighth Edition. Guide for the Care and Use of Laboratory Animals, National Academies Press (US); Washington: 103. pp. 1072–1073. 2010
18	Li Y, Gao J, Wang G and Fei G: Latent cytomegalovirus infection exacerbates experimental pulmonary fibrosis by activating TGF-β1. Mol Med Rep. 14:1297–1301. 2016. View Article : Google Scholar : PubMed/NCBI
19	Banczyk D, Kalies K, Nachbar L, Bergmann L, Schmidt P, Bode U, Teegen B, Steven P, Lange T, Textor J, et al: Activated CD4⁺ T cells enter the splenic T-cell zone and induce autoantibody-producing germinal centers through bystander activation. Eur J Immunol. 44:93–102. 2014. View Article : Google Scholar
20	Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW and Crystal RG: Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis. 120:893–899. 1979.PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
22	Labzin LI, Lauterbach MA and Latz E: Interferons and inflammasomes: Cooperation and counterregulation in disease. J Allergy Clin Immunol. 138:37–46. 2016. View Article : Google Scholar : PubMed/NCBI
23	Walsh JG, Muruve DA and Power C: Inflammasomes in the CNS. Nat Rev Neurosci. 15:84–97. 2014. View Article : Google Scholar : PubMed/NCBI
24	Masood H: Inflammasomes in the pathophysiology of kidney diseases. Kidney Dis (Basel). 1:187–193. 2015. View Article : Google Scholar
25	Yang CA and Chiang BL: Inflammasomes and human autoimmunity: A comprehensive review. J Autoimmun. 61:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
26	Sierro S, Rothkopf R and Klenerman P: Evolution of diverse antiviral CD8⁺ T cell populations after murine cytomegalovirus infection. Eur J Immunol. 35:1113–1123. 2005. View Article : Google Scholar : PubMed/NCBI
27	Restrepo-Gualteros SM, Jaramillo-Barberi LE, Gonzalez-Santos M, Rodriguez-Martinez CE, Perez GF, Gutierrez MJ and Nino G: Characterization of cytomegalovirus lung infection in non-HIV infected children. Viruses. 6:2038–2051. 2014. View Article : Google Scholar : PubMed/NCBI
28	Hoshino T, Nakamura H, Okamoto M, Kato S, Araya S, Nomiyama K, Oizumi K, Young HA, Aizawa H and Yodoi J: Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med. 168:1075–1083. 2003. View Article : Google Scholar : PubMed/NCBI
29	Boger DL and Cai H: Bleomycin: Synthetic and mechanistic studies. Angewandte Chemie Int Edition. 38:448–476. 2010. View Article : Google Scholar
30	Gwinn WM, Kapita MC, Wang PM, Cesta MF and Martin WJ II: Synthetic liposomes are protective from bleomycin-induced lung toxicity. Am J Physiol Lung Cell Mol Physiol. 301:L207–L217. 2011. View Article : Google Scholar : PubMed/NCBI
31	Hofman K, Hall B, Cleaver H and Marshall S: High-throughput quantification of hydroxyproline for determination of collagen. Anal Biochem. 417:289–291. 2011. View Article : Google Scholar : PubMed/NCBI
32	Zhan H, Huang F, Ma W, Zhao Z, Zhang H and Zhang C: Protective effect of ginsenoside Rg1 on bleomycin-induced pulmonary fibrosis in rats: Involvement of caveolin-1 and TGF-β1 signal pathway. Biol Pharm Bull. 39:1284–1292. 2016. View Article : Google Scholar
33	Banczyk D, Kalies K, Nachbar L, Bergmann L, Schmidt P, Bode U, Teegen B, Steven P, Lange T, Textor J, et al: Activated CD4⁺ T cells enter the splenic T-cell zone and induce autoantibody-producing germinal centers through bystander activation. Eur J Immunol. 44:93–102. 2014. View Article : Google Scholar
34	Guarda G, Dostert C, Staehli F, Cabalzar K, Castillo R, Tardivel A, Schneider P and Tschopp J: T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature. 460:269–273. 2009. View Article : Google Scholar : PubMed/NCBI
35	Viganò E and Mortellaro A: Caspase-11: The driving factor for noncanonical inflammasomes. Eur J Immunol. 43:2240–2245. 2013. View Article : Google Scholar : PubMed/NCBI
36	Cheresh P, Kim SJ, Tulasiram S and Kamp DW: Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta. 1832:1028–1040. 2013. View Article : Google Scholar :
37	Saïd-Sadier N and Ojcius DM: Alarmins, inflammasomes and immunity. Biomed J. 35:437–449. 2012. View Article : Google Scholar
38	Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, Schnyder B, Akira S, Quesniaux VF, Lagente V, et al: IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest. 117:3786–3799. 2007.PubMed/NCBI
39	Guerville F, Daburon S, Marlin R, Lartigue L, Loizon S, Pitard V, Couzi L, Moreau JF, Déchanet-Merville J and Faustin B: TCR-dependent sensitization of human gammadelta T cells to non-myeloid IL-18 in cytomegalovirus and tumor stress surveillance. Oncoimmunology. 4:e10030112015. View Article : Google Scholar
40	Schroder K and Tschopp J: The inflammasomes. Cell. 140:821–832. 2010. View Article : Google Scholar : PubMed/NCBI
41	Mankan AK, Kubarenko A and Hornung V: Immunology in clinic review series; focus on autoinflammatory diseases: Inflammasomes: Mechanisms of activation. Clin Exp Immunol. 167:369–381. 2012. View Article : Google Scholar : PubMed/NCBI
42	Bromley SK, Mempel TR and Luster AD: Orchestrating the orchestrators: Chemokines in control of T cell traffic. Nat Immunol. 9:970–980. 2008. View Article : Google Scholar : PubMed/NCBI
43	Luzina IG, Todd NW, Sundararajan S and Atamas SP: The cytokines of pulmonary fibrosis: Much learned, much more to learn. Cytokine. 74:88–100. 2015. View Article : Google Scholar
44	Zhou XM, Wen GY, Zhao Y, Liu YM and Li JX: Inhibitory effects of alkaline extract of Citrus reticulata on pulmonary fibrosis. J Ethnopharmacol. 146:372–378. 2013. View Article : Google Scholar : PubMed/NCBI
45	Yu HB and Finlay BB: The caspase-1 inflammasome: A pilot of innate immune responses. Cell Host Microbe. 4:198–208. 2008. View Article : Google Scholar : PubMed/NCBI
46	Kong H, Wang Y, Zeng X, Zhu Q, Xie W and Dai S: Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: A case report. J Clin Pharm Ther. 39:691–694. 2014. View Article : Google Scholar : PubMed/NCBI
47	De Nardo D, De Nardo CM and Latz E: New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. Am J Pathol. 184:42–54. 2014. View Article : Google Scholar :
48	Artlett CM, Sassi-Gaha S, Rieger JL, Boesteanu AC, Feghali-Bostwick CA and Katsikis PD: The inflammasome activating caspase 1 mediates fibrosis and myofibroblast differentiation in systemic sclerosis. Arthritis Rheum. 63:3563–3574. 2011. View Article : Google Scholar : PubMed/NCBI
49	Huang TT, Lai HC, Ko YF, Ojcius DM, Lan YW, Martel J, Young JD and Chong KY: Hirsutella sinensis mycelium attenuates bleomycin-induced pulmonary inflammation and fibrosis in vivo. Sci Rep. 5:152822015. View Article : Google Scholar : PubMed/NCBI
50	Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT and Tschopp J: Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 320:674–677. 2008. View Article : Google Scholar : PubMed/NCBI
51	Xu JF, Washko GR, Nakahira K, Hatabu H, Patel AS, Fernandez IE, Nishino M, Okajima Y, Yamashiro T, Ross JC, et al: Statins and pulmonary fibrosis: The potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med. 185:547–556. 2012. View Article : Google Scholar : PubMed/NCBI
52	Tong CY, Bakran A, Williams H, Cuevas LE, Peiris JS and Hart CA: Association of tumour necrosis factor alpha and interleukin 6 levels with cytomegalovirus DNA detection and disease after renal transplantation. J Med Virol. 64:29–34. 2001. View Article : Google Scholar : PubMed/NCBI
53	Contreras A, Botero JE and Slots J: Biology and pathogenesis of cytomegalovirus in periodontal disease. Periodontol 2000. 64:40–56. 2014. View Article : Google Scholar